These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19211366)

  • 21. Adjuvant radiotherapy for phyllodes tumor of breast.
    Chaney AW; Pollack A; McNeese MD; Zagars GK
    Radiat Oncol Investig; 1998; 6(6):264-7. PubMed ID: 9885942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Partial breast irradiation: high dose rate peroperative brachytherapy technique using the MammoSite].
    Belkacémi Y; Chauvet MP; Giard S; Poupon L; Castellanos ME; Villette S; Bonodeau F; Cabaret V; Lartigau E
    Cancer Radiother; 2003 Nov; 7 Suppl 1():129s-136s. PubMed ID: 15124555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer first results of the randomized Budapest boost trial.
    Polgár C; Fodor J; Orosz Z; Major T; Takácsi-Nagy Z; Mangel LC; Sulyok Z; Somogyi A; Kásler M; Németh G
    Strahlenther Onkol; 2002 Nov; 178(11):615-23. PubMed ID: 12426672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective.
    Gebski V; Lagleva M; Keech A; Simes J; Langlands AO
    J Natl Cancer Inst; 2006 Jan; 98(1):26-38. PubMed ID: 16391369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
    Fodor J; Polgár C; Major T; Németh G
    Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.
    Niehoff P; Dietrich J; Ostertag H; Schmid A; Kohr P; Kimmig B; Kovács G
    Strahlenther Onkol; 2006 Feb; 182(2):102-7. PubMed ID: 16447017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy.
    Vordermark D; Lackenbauer A; Wulf J; Guckenberger M; Flentje M
    Oncol Rep; 2007 Nov; 18(5):1335-9. PubMed ID: 17914594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity.
    Alektiar KM; Brennan MF; Singer S
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):202-8. PubMed ID: 16111590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiotherapy after segmental resection of breast cancer with favorable prognostic features: 12-year follow-up results of a randomized trial.
    Holli K; Hietanen P; Saaristo R; Huhtala H; Hakama M; Joensuu H
    J Clin Oncol; 2009 Feb; 27(6):927-32. PubMed ID: 19114687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective evaluation of concomitant tumour bed boost with whole breast irradiation in patients with locally advanced breast cancer undergoing breast-conserving therapy.
    Jalali R; Malde R; Bhutani R; Budrukkar A; Badwe R; Sarin R
    Breast; 2008 Feb; 17(1):64-70. PubMed ID: 17851077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer of the breast. Radiation therapy.
    Mercado R; Deutsch M
    Major Probl Clin Surg; 1979; 5():350-60. PubMed ID: 88550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial breast irradiation: revolution or evolution?
    Hannoun-Levi JM; Mazeron JJ; Marsiglia H; Gerard JP
    Cancer Treat Rev; 2004 Nov; 30(7):599-607. PubMed ID: 15531394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial.
    Poortmans P; Bartelink H; Horiot JC; Struikmans H; Van den Bogaert W; Fourquet A; Jager J; Hoogenraad W; Rodrigus P; Wárlám-Rodenhuis C; Collette L; Pierart M;
    Radiother Oncol; 2004 Jul; 72(1):25-33. PubMed ID: 15236871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.